Search
Letterer-Siwe disease
go.drugbank.com/conditions/DBCOND0021755Drugs: VinblastineSynonyms: Langerhans cell histiocytosis, no ICD-O subtype, Langerhans cell histiocytosis, no International Classification of Diseases for Oncology subtypeDiazoxide
go.drugbank.com/drugs/DB01119ApprovedInvestigational[A255647,L44612] It is chemically related to thiazide diuretics but does not inhibit carbonic anhydrase and does not have chloriuretic or natriuretic activity. … [A190372] When administered intravenously, diazoxide can be used to treat hypertensive emergencies;[L44622] however, this specific form of diazoxide is no longer available in the US.
Categories: Arteriolar Smooth Muscle, Agents Acting OnMaraviroc
go.drugbank.com/drugs/DB04835ApprovedInvestigationalMaraviroc (brand-named Selzentry, or Celsentri outside the U.S.) is a chemokine receptor antagonist drug developed by the drug company Pfizer that is designed to act against HIV by interfering with the … It was originally labelled as UK-427857 during development but was assigned the Maraviroc name as it entered trials. It was approved for use by the FDA in August, 2007.
Categories: CCR5 Co-receptor AntagonistOxolamine
go.drugbank.com/drugs/DB13216ApprovedOxolamine is not approved in the USA, it may be marketed elsewhere internationally as a cough suppressant [L5416]. It is listed as a prescription drug in New Zealand legislation [L5419].
Mecasermin rinfabate
go.drugbank.com/drugs/DB14751ApprovedInvestigationalMecasermin rinfabate manufactured by Insmed Incorporated under the brand name Iplex was approved by the FDA in 2005[L5722]. … The binding of IGF-1 to IGFBP-3 is said to extend the half life and reduce the clearance of IGF-1 in patients with growth hormone resistant syndromes and low levels of IGFBP-3 though this may represent
Panobinostat
go.drugbank.com/drugs/DB06603ApprovedInvestigationalPanobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. … The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted
Synonyms: (2E)-N-hydroxy-3-[4-({[2-(2-methyl-1H-indol-3-yl)ethyl]amino}methyl)phenyl]acrylamide, 2-PROPENAMIDE, N-HYDROXY-3-(4-(((2-(2-METHYL-1H-INDOL-3-YL)ETHYL)AMINO)METHYL)PHENYL)-, (2E)-Arbutamine
go.drugbank.com/drugs/DB01102ApprovedArbutamine, administered through a closed-loop, computer-controlled drug-delivery system, is indicated to elicit acute cardiovascular responses, similar to those produced by exercise, in order to aid in
Ephedrine
go.drugbank.com/drugs/DB01364ApprovedInvestigational[L12972] Ephedrine and [phenylephrine] are still used to treat hypotension, but their use in other indications has decreased due to the development of more selective adrenergic agonists. … [A193701,A193704,L12975] Ephedrine was granted a type 7 FDA Approval on 29 April 2016.[L12975]
Mixtures: NEO NAPACIN, NEO YEKASTHMACarbinoxamine
go.drugbank.com/drugs/DB00748ApprovedThis antagonizes the effects of histamine on HA-receptors, leading to a reduction of the negative symptoms brought on by histamine HA-receptor binding. … The product label for carbinoxamine as an over the counter cough and cold medicine is being modified to state "do not use" in children under 4 years of age in order to prevent and reduce misuse, as many
Bacitracin
go.drugbank.com/drugs/DB00626ApprovedInvestigationalVet approved[A181952] Bacitracin was granted FDA approval on 29 July 1948.[A181997,L7748]
Mixtures: Bus and Classroom Yellow, Care Bus and Classroom Yellow